5 Most Undervalued Financial Stocks to Buy Now

Key Takeaways

• UBS cut Lazard target to $48, maintaining neutral rating.
• Goldman Sachs lowered target to $46, issuing sell recommendation.
• AUM reached $277.7B, with $8.9B appreciation.
• Investment‑banking volumes rose 4% YoY, growth slowing.
• Stock down ~15% YTD, multiple compression suggests undervaluation.

Summary

Lazard (NYSE:LAZ) slipped 0.37% as UBS and Goldman Sachs trimmed price targets to $48 and $46 respectively, shifting to neutral and sell ratings. The firm reported $277.7 billion in assets under management, buoyed by $8.9 billion of market appreciation and $4.2 billion of net inflows, offset by modest FX losses and a stake sale. Investment‑banking volumes rose 4% year‑over‑year but are decelerating amid geopolitical uncertainty. Lazard’s stock is down roughly 15% YTD, reflecting multiple compression that many analysts view as a buying opportunity.

Pulse Analysis

Lazard’s recent price‑target reductions underscore a broader market reassessment of financial‑services firms. While UBS and Goldman Sachs have lowered expectations, the firm’s diversified revenue streams—spanning investment banking, asset management, and advisory—remain resilient. Analysts cite the 4% year‑over‑year rise in deal volumes as a sign that M&A activity is still robust, even as geopolitical tensions threaten to dampen momentum. This nuanced view creates a valuation gap, positioning Lazard as a potentially attractive entry point for value‑oriented investors.

The firm’s assets under management climbed to $277.7 billion, driven largely by $8.9 billion of market appreciation and $4.2 billion of net inflows. These inflows reflect client confidence in Lazard’s asset‑allocation expertise, while the modest foreign‑exchange depreciation and the $1.5 billion divestiture of Edgewater Funds illustrate disciplined capital management. A growing AUM base typically translates into higher fee revenue, enhancing earnings stability amid volatile market conditions. For investors, the AUM trajectory offers a tangible metric of operational strength beyond headline earnings.

From a valuation perspective, Lazard’s stock has underperformed the broader S&P 500, falling about 15% year‑to‑date and experiencing multiple compression relative to peers. This discount, combined with a middle‑stage M&A cycle and a constructive long‑term outlook, suggests upside potential if deal flow steadies and earnings normalize. Market participants should monitor upcoming earnings releases and any revisions to analyst price targets, as these will clarify whether the current undervaluation is a temporary market overreaction or a signal of deeper sector challenges.